Form 4: Ionis Director Sells Shares Under 10b5-1 Plan

Ionis Pharmaceuticals Director Joseph H. Wender sold 27,900 shares of common stock in late October 2025 under a pre-arranged 10b5-1 trading plan.

Summary

• Director Joseph H. Wender sold a total of 27,900 shares of Ionis Pharmaceuticals Inc. common stock.
• The sales occurred on October 30, 2025, and October 31, 2025.
• These transactions were executed pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 26, 2024.
• The shares were sold at weighted average prices ranging from $72.19 to $75.1586 per share.
• Following these transactions, Joseph H. Wender beneficially owns 64,035 shares indirectly through a trust.

Sentiment

Score: 5

Explanation: The sales are pre-planned under a 10b5-1 plan, which mitigates the negative signal typically associated with insider selling, making the transaction largely neutral in terms of immediate sentiment.

Positives

• The sales were conducted pursuant to a Rule 10b5-1 Trading Plan adopted on December 26, 2024, indicating the transactions were pre-scheduled and not based on immediate, non-public information.

Negatives

• A director of the company reduced their beneficial ownership by selling a significant number of shares.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may interpret the director's reduction in holdings as a signal, though the pre-planned nature under Rule 10b5-1 lessens the immediate concern regarding the timing of the sale.

Key Dates

Recommendation

The director's sale of shares, while significant in volume, was executed under a pre-arranged 10b5-1 trading plan. This indicates the decision to sell was made well in advance and not based on recent material non-public information, thereby reducing the negative signal typically associated with insider selling. Without additional context on the company's performance or strategic direction, this transaction alone does not warrant a change from a 'hold' position.

Keywords

Ionis Pharmaceuticals, IONS, Joseph H. Wender, Form 4, Insider Trading, Stock Sale, Director, 10b5-1 Plan